- Home
- DNA vs MGTX Comparison
DNA vs MGTX Comparison
Compare DNA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNA
- MGTX
- Stock Information
- Founded
- DNA 2008
- MGTX 2015
- Country
- DNA United States
- MGTX United States
- Employees
- DNA N/A
- MGTX N/A
- Industry
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNA Health Care
- MGTX Health Care
- Exchange
- DNA Nasdaq
- MGTX Nasdaq
- Market Cap
- DNA 731.1M
- MGTX 670.2M
- IPO Year
- DNA N/A
- MGTX N/A
- Fundamental
- Price
- DNA $10.74
- MGTX $7.34
- Analyst Decision
- DNA Hold
- MGTX Strong Buy
- Analyst Count
- DNA 2
- MGTX 2
- Target Price
- DNA $9.50
- MGTX $24.00
- AVG Volume (30 Days)
- DNA 1.6M
- MGTX 284.2K
- Earning Date
- DNA 11-11-2025
- MGTX 11-12-2025
- Dividend Yield
- DNA N/A
- MGTX N/A
- EPS Growth
- DNA N/A
- MGTX N/A
- EPS
- DNA N/A
- MGTX N/A
- Revenue
- DNA $230,815,000.00
- MGTX $37,917,000.00
- Revenue This Year
- DNA N/A
- MGTX $145.67
- Revenue Next Year
- DNA $13.73
- MGTX $167.61
- P/E Ratio
- DNA N/A
- MGTX N/A
- Revenue Growth
- DNA 25.21
- MGTX 366.84
- 52 Week Low
- DNA $5.00
- MGTX $3.94
- 52 Week High
- DNA $16.85
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- DNA 44.20
- MGTX 42.39
- Support Level
- DNA $9.95
- MGTX $7.21
- Resistance Level
- DNA $11.97
- MGTX $7.91
- Average True Range (ATR)
- DNA 0.79
- MGTX 0.36
- MACD
- DNA -0.16
- MGTX -0.01
- Stochastic Oscillator
- DNA 25.19
- MGTX 18.18
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.